medRxiv preprint doi: https://doi.org/10.1101/2024.02.16.24302914; this version posted February 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

One effect and two causes: Growth acceleration and breast cancer risk after hormone 1 2 replacement therapy 3 Dieter Hölzel<sup>1</sup>, Anne Schlesinger-Raab<sup>1</sup>, Kathrin Halfter<sup>1</sup> 4 5 <sup>1</sup> Dieter Hölzel, Prof. 6 Institute of Medical Information Processing, Biometry and Epidemiology (IBE), Faculty of 7 Medicine, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany. 8 hoe@ibe.med.uni-muenchen.de 9 10 <sup>1</sup> Anne Schlesinger-Raab, Dr. Institute of Medical Information Processing, Biometry and Epidemiology (IBE), Faculty of 11 Medicine, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany. 12 schlesi@ibe.med.uni-muenchen.de 13 14 15 <sup>1</sup> Kathrin Halfter, Dr. 16 Institute of Medical Information Processing, Biometry and Epidemiology (IBE), Faculty of Medicine, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany. 17 halfter@ibe.med.uni-muenchen.de 18 19 20 Corresponding author: 21 22 23 Dr. Kathrin Halfter 24 Institute of Medical Information Processing, Biometry and Epidemiology (IBE), Faculty of 25 Medicine, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany. 26 Email: halfter@ibe.med.uni-muenchen.de Telephone: 089 4400 74486 27 28 Funding: None 29 Keywords 30 31 Breast cancer, hormone replacement therapy, tumor growth, risk factors, models 32 382 words 33 Abstract: 34 Text: 3.376 words without References 35 References: 35.981 words 36 Figures: 3 37 38 Abbreviations: 39 BC 40 Breast cancer GD Growth duration of BCs 41 GAF Growth acceleration factor 42 43 HT Hormone replacement therapy 44 HTD Hormone replacement therapy duration 45 HR+/- Hormone receptor positive/negative 46 MET Metastasis, metastases 47 MWS Million Women Study RF 48 BC risk factor relative risk 49 RR Volume doubling time VDT 50 51 WHI-S Women's Health Initiative Studies

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 52 Abstract: 382 Words

53

### 54 Background

55 An increased risk for breast cancer (BC) following hormone replacement therapy (HT) with 56 estrogen and progesterone in women has been reported in several studies. However, HTs are 57 associated with two distinct effects, a BC risk (RF) and an acceleration of BC growth (GAF). 58 The interaction of both effects is analyzed.

59

### 60 Methods

Using data from the U.S. population on BC incidence and life expectancy specific cohorts and 61 62 their disease trajectories are modelled. First, age-specific BCs are randomly generated for the age interval 50-80 years based on public data. Second, this simulated cohort subsequently 63 64 receives a HT over 4 years that accelerates the growth of prevalent BCs. In a third cohort additional BCs are simulated caused by HT under treatment. The cumulative incidence of BCs 65 is modelled for up to 30 years using different assumptions on BC growth duration, GAF and 66 RF, as well as the duration of HT. The Women's Health Initiative Study (WHI-S) is also 67 simulated in a fourth cohort assuming a GAF 1.4 and RF 2.0. 68

69

#### 70 Results

Studies modelling the risk of BC after HT imply two main findings: First, the growth of prevalent BCs is accelerated in parallel to the start of HT. This results in an increased BC incidence where the relative risk is equivalent to the GAF. The duration of HT defines the turning point of this increase. The second finding demonstrates that during the 15 years of BC growth an inherent RF for BC through HTs becomes observable only after a comparable delay. The combined effect results in an overlap of age-specific BCs, which develop at the same time, both growing faster under HT.

Varying parameters can explain different results in the WHI-S. According to the WHI almost 6
million women decided to discontinue or not to start HT. This offers a valid explanation
(assuming a GAF 2) for the 10% decline in incidence around 2002. Estimates which report one

- 81 million additional BCs associated with HT in Western countries since 1990 can thus, for the
- 82 most part, be attributed to more rapidly growing prevalent BCs.
- 83

# 84 Conclusion

- 85 HT accelerates the growth of prevalent BCs and can also cause BCs which become
- symptomatic after 10 or more years. In combination these effects increase BC incidence.
- 87 Differentiated information on these inherent risks and benefits should support shared decision-
- 88 making for HT.

## 89 Introduction

Hormone replacement therapies (HT) have been used in different forms for more than 70 90 years, at the same time the discussion on their risks and benefits has not abated. <sup>1,2</sup> Reasons 91 for the continued controversy surrounding HT include side effects such as increased risks of 92 breast cancer (BC), endometrial cancer, dementia, and stroke, while also reducing the risk of 93 diabetes, fractures or colorectal cancer.<sup>3</sup> The medical indication of HT for menopausal 94 symptoms remains relevant to women's health care. Data on the increased risk of breast 95 cancer (BC) due to combined HTs with estrogen and progesterone were presented in 2002 by 96 the Women's Health Initiative Studies (WHI-S). The publication and subsequent change in HT 97 prescription patterns resulted in a marked decrease in BC incidence in the USA. <sup>4,5</sup> Further 98 data on HT and BC risk are available from the Million Women Study (MWS) <sup>6</sup> and from meta-99 analyses (Meta-A). <sup>7,8</sup> Meta-A estimated that 1 million BCs were caused by HT in the first 5 100 101 years after onset in Western countries since 1990, but with the following condition that: "...if 102 these associations are largely causal...". We hypothesize that HTs do result in additional BCs caused by a combination of two effects, an acceleration of growth of prevalent BCs and 103 104 increased BC risk. In this modelling study we examine the interaction of these two effects and 105 estimate the risk for HT users.

### 106 Methodology

Four cohorts of female patients are randomly generated in order to model the effects of HT
 according to normal life expectancy and the incidence from SEER Cancer Statistics Review,
 1975-2002 <sup>9</sup>:

- BCs are randomly generated within a virtual cohort of 100,000 50 year old women over an
   observation period of 30 years taking life expectancy into account. <sup>9,10</sup> This cohort serves as
   the control group.
- 2) The control cohort receives HT. The HT effect is estimated using the duration of BC growth(GD), the duration of HT (HTD), and a growth acceleration factor (GAF).

3) A risk factor (RF) takes effect, which becomes relevant in the initiation of additional BCs
through HT. Both effects, the faster growth in the second cohort and an increased BC risk
are combined in this third cohort, starting and ending with HT.

4) Endocrine prevention is modelled in a separate cohort for additional comparison.

For hormone receptor positive (HR+) BCs, initial modelling is performed with the parameters GD of 15 years, HTD of 4 years and the factor 2 as GAF and RF. This RF of 2 is taken from the Gail model, which was used to recruit participants for chemoprevention studies. <sup>11</sup> Briefly, these studies show that even 15 years after the end of prevention therapy, the incidence was cut in half and thus concluded that HR+ BCs grow for at least 15 years <sup>12,13</sup>

The growth of BCs can be described using volume doubling times (VDT). VDTs of 72 and 170 124 days are used for HR- and HR+ BCs, respectively. These values are the mean VDT from two 125 studies. <sup>14,15</sup> This means, for example, that 10.5 volume doublings (VD) or 2.1/4.9 years are 126 required for the growth of HR-/HR+ BC from 2.5mm (pT1a) to 28.0mm (pT2). After 33 VD a 127 20.0mm BC with about 8,6 billion cells has developed from one cancerous cell, which takes 128 129 15.4 years in HR+ BC. This time span is comparable to the GD introduced above. A GAF of 2 can also be considered biologically plausible, as shown by the 2.4-fold faster growth of HR-130 131 versus HR+ BCs. These values given above are then used to generate growth trajectories and adjusted BC diagnosis timelines (see Fig. 1). 132

133 Comparison and modelling of the WHI-S uses published data such as age distribution and 134 hazard ratios of cumulative incidences to estimate GAF and RF. Statistical analyses and 135 modelling using data matrices of 3 million elements for e.g. 100,000 test persons and their 136 events over a period of 30 years were done using the R-System version 3.1.3 <sup>16</sup>.

## 137 Results

## 138 Simulation of BC incidence with plausible model parameters for BC risk and growth

139 acceleration due to HT

The time-dependent GAF effect of HT on disease trajectories is described in Fig. 1. The interaction with RF and the resulting BC incidence estimate is shown in Fig. 2. In the example with 100,000 virtual test persons 119+263+281+248 BCs were generated in the first 4 years of the control group (SD ± 11-17). For the next 30 years, there are 9,961 BCs and 27,612 deaths without BC to expect. Two years of endocrine prevention would eradicate an estimated 2,731 or 27.3% BCs, assuming 50% treatment efficacy.

146 The cumulative incidences show 3 inflection points (Fig.2): Period 1 ends after HTD/GAF years and gives the best estimate for the relative risk (RR), which is equivalent to GAF. The 911 BCs 147 diagnosed in the control group within the first 4 years become detectable a maximum 2 years 148 149 earlier through HT. The incidence is thereby effectively doubled during this period (cohort 2). The RR decreases during Period 2. At the beginning of Period 3 (GD-HTD\*((GAF-1)/GAF) the 150 incidence in the HT group decreases up to Period 4 (GD+HTD). In the risk group (cohort 3), 151 the incidence increases in Period 3 until the end of the BC risk enhancing HT. Both prevalent 152 153 and new BC types are exposed to HT between 0 and 4 years. When the GAF and RF factors are equal, the cumulative incidence shows no effect. In Period 4, after 19 years, the HT effect 154 on BC risk returns to the "naturally" expected value. Fig.2C-D show the inflection point's 155 dependence of the RR in a year-on-year comparison. 156

157 Women Health Initiative Studies

The observational WHI-S reported a RR of 2 for BC in the first years. The same risk was modelled with GAF 2 in Fig. 2. <sup>17</sup> The WHI-S with 16,121 women showed a cumulative incidence congruent to the simulation illustrated in Fig. 2 of this article. <sup>18</sup> In a separate randomized study the WHI presented different results. Herein 8,506 women were recruited for combination HT, their age distribution, study cancellation after 5.6 years, life expectancy and the inclusion criterion of a negative mammogram are available data from the study. The

164 cumulative hazard rates after 5.6/24 years were 1.26/1.28. <sup>4,5,19</sup>. Using this data from the 165 randomized study the two factors can be estimated and under the specification of GAF 1.4 and 166 RF 2.0 a study replicate model was generated (Fig.3).

The age distribution of the study model resulted in a mean of 63.5 years (WHI-S 63.4 years).
As in the most recent publication the median age after 24 years of follow-up was 82.0 years,
and 3,182 of the 8,506 patients in the HT group were still at risk.

After 8 years, 296/262 (RR 1.22 CI: 1.02-1.45) and after 24 years 761/609 (RR 1.27 CI: 1.14-170 1.41) BCs were generated in the two groups with/without HT. This can be compared to data of 171 the WHI-S which are 277/207 after 8 years and 584/447 after 24 years. The most striking 172 173 difference between the original and the modelled study was found in the first 4 years (Fig.3B), in which the randomized WHI-S even shows a protective effect of HT.<sup>5</sup> In the first year 13/27 174 BCs were generated (Fig.3C) in the modelled study, which also shows the time dependence 175 of the RR with large confidence intervals due to small case numbers (Fig.3D). Thirty years of 176 complete follow-up also explain the higher number of cases. Overall, the WHI-S can be 177 reproduced with the two factors GAF 1.4 and RF 2 except for the first few years. 178

### 179 The Million women study and Meta analyses

The results of the updated Meta-A summarize data from 58 prospective and retrospective 180 181 studies with a total of 143,887 BCs and 424,972 controls. <sup>7,20</sup> Data on BC risk by histological type in the MWS was presented in 2006 and showed an RR of 1.71 for ductal BC with a 182 treatment duration of 3.4 years for combination HT. <sup>6</sup> Fig.3C-D also shows large RRs at the 183 beginning due to the high risk after a negative mammogram. The Meta-A results show an 184 185 increase in RR, which reaches 2.26/2.51 in women taking HT with treatment durations of 10-14/≥ 15 years. However, there is no continuous increase in risk in any simulation with longer 186 HT. It is therefore remarkable that there appears to be a decrease in the RR to 1.2-1.3 for 187 women who had undergone HT in the first 5 years after the end of long HTs. The findings 188 189 correspond to those seen Fig.3D. The changes in RR are not available over the course of the years, not even for the excellent MWS with 43,022 BCs and 169,041 controls. Only the 190

increased BC mortality after 20 years is available <sup>21</sup>, but no details on the prognostic factors of the BCs that occurred during the course. This data are important to better understand the circumstances of the estimated one million additional BCs caused by HT worldwide. <sup>7</sup> But detailed data on various drugs, the onset and duration of HT and long-term follow-up are needed in order to provide reliable estimates for GAF and RF in simulations.

## 196 **Discussion**

The effect of HT with estrogen and progesterone is modelled based on currently known facts on tumor growth. The median time from tumor initiation to METs in HR-/HR+ BCs is 5/10 years. <sup>22</sup> Since BCs grow more slowly, the 1.5-fold growth time for BC is plausible. A BC growth over 15 years is also shown in prevention studies for HR+ BCs. <sup>12</sup> Therefore, there are 2 effects caused by HT: A growth acceleration and a BC risk, represented by GAF and RF. Available data can be simulated, modelled, and reinterpreted considering these two factors.

#### 203 Growth acceleration GAF

204 An accelerated growth causes the increase in incidence at the beginning of HT (Fig. 1). Other 205 published findings on HT and breast biology support these findings, for example HTs can increase breast density and cell activity in the short term and BCs diagnosed during HT are 206 more likely luminal A-like <sup>23</sup>. In addition, elevated Ki67 levels indicate increased proliferation 207 even in healthy breast tissue due to HT.<sup>24</sup> Furthermore, there is no evidence that dormant BCs 208 exist and can be reactivated. Therefore, the estimated one million BCs are likely to be 209 prevalent, not yet detectable, only faster-growing BCs. This can also be corroborated by the 210 MWS with a reported RR 1.45 after one year of HT use. <sup>7,20</sup> As the modelling in Fig.2 shows, 211 212 a constant RR is to be expected from the beginning of HT, which is equivalent to the GAF. This phase lasts for the time limit of HTD/GAF. 213

A closer look at the initial time period can also be revealing: If negative mammograms in the first few months after the onset of a study suggest lower incidences, a GAF should result in an extremely high RR in the first few months, even with small numbers of patients in the studies (Fig. 2-3). The time dependence can be described overall by reporting the annual BCs, the RR, or at best continuously with the cumulative incidence in the study and control arms of a study. The observational WHI study shows this initial effect with an RR of 2 (see also Fig. 2).

If HT causes faster growth of HR+ BCs, this would mean that in HT users larger BCs and BCs with an increased number of positive LNs are diagnosed. During screening more interval cancers were reported and the BCs spread earlier, which would increase mortality. <sup>19,20</sup>

However, the increase in mortality in the WHI-S is not significant even after 20 years. This finding is due to the number of cases, but also to a follow-up period which is too short because initiated BCs mostly occur after 15 years and METs occur a further 15 to 20 years later. <sup>18</sup> An average tumor diameter of 17/15.0mm is reported for BCs with/without HT <sup>19</sup>, which results in a mortality rate of 84.6/87.4% after 15 years. <sup>25</sup>

#### 228 Wash-out phase

As HT users were also recruited for the studies, the wash-out time must be taken into account. 229 230 <sup>19</sup> Together with other inclusion and exclusion criteria, this improves the homogeneity of the study groups. However, a GAF and RF effect of HT is certainly not reversible. That is why 231 there is no safe wash-out interval. <sup>26</sup> An interruption of HT results in intermittent growth, after 232 restarting HT the accelerated growth and the associated BC risk returns. As for the BC risk, its 233 234 relationship to the duration of HT has to be considered as well. If HT is used for the first time at the onset of the study, age-specific BCs are bound to occur at the same time as the BCs 235 caused by HT. The growth of both BCs is accelerated by HT and they occur in the Period 3 236 interval. This reasoning appears plausible because neither prevention studies nor adjuvant 237 238 therapies reveal an efficacy window: They affect all BCs, large and small prevalent BCs. Since BCs are not eliminated by the wash-out time, the durations before and after the start of the 239 study must be added together for past users. With HT durations of more than 10 years and a 240 GAF of 2 the first HT-induced BCs will occur during HT; the two effects overlap. This explains 241 242 the increasing RR in the Meta-A study for HT users of 10-14 and >15 years. So far, there is no biological explanation, no memory for the duration of HT and a RF that increases with HTD. 243

### 244 The decline in incidence

With the end of HT its effects also stop. This is shown by the marked drop in BC incidence in 245 the U.S. reported for 2002 following the publication of the WHI-S. 9,27 In 2002 203,500 BCs 246 were expected in the U.S., in 2008 only 182,460<sup>28,29</sup>. In the age interval between 50 and 70 247 years, the incidence was 356 per 100 000. A decrease in the incidence of 21,040 (10.3%) BCs 248 would be explained by 5.9 million women foregoing HT under the assumption of a GAF of 2. 249 This decline is explained by the simultaneous renunciation of HTs and cancellation of ongoing 250 HTs. Approximately 20 million fewer prescriptions were made in 2003 compared to 2002, or a 251 decrease of approximately 5 million HTs from 2001 to 2003 reported for the whole U.S. 252 population <sup>30,31</sup> A further explanation, such as a regression of prevalent BCs through 253 withdrawal of millions of HTs, is not required for this rapid decline. In addition, this decline 254 confirms that switching growth acceleration on and off responds guickly and that BC risk at all 255 does not play a role in this short-term decline. As the two effects GAF and RF cannot be 256 reversed by stopping HT, the stop still has an effect corresponding to the GD for 15 years. Until 257 2018, the incidence shows no clear trend, which speaks in favor of compensation and thus 258 equal effects of GAF and RF (Fig. 2C). <sup>27</sup> 259

The HT effect can also explain the long-term incidence trend in the USA. The temporary increase due to screening in the 1980s continued with the increasing utilization of HT until 2001. In 2006, the incidence was the same as in 1986. <sup>9</sup> Following the publication of the missing prevention of heart disease and side effects of HT study <sup>32</sup>, incidence and HT utilization began to decline. This was historically unique reaction in a population due to the 2002 WHI-S publication. This suggests that the incidence peak between 1986 and 2002 was an artefact merely bringing prevalent BCs forward through screening and HT.

267 Open questions

HTs cause BC growth acceleration and have an additional BC risk. Even with short HTs, the effects overlap in the range of the growth duration of BCs at around 15 years. The effects such as those on cell activity and breast density change in the short term. Therefore, the time

dependence of the effects must be analyzed continuously with up to 30 years of follow-up.
Even if this allows reliable conclusions to be drawn for patients, many questions regarding the
quantification of the effects remain unanswered.

274 How does the growth of BCs depend on the estrogen and progesterone receptors and molecular subtype? Does it depend on the duration of HT or on age? Can a GAF in HR+ BCs 275 even approach the 2.5-fold growth of triple negative BCs and how does this correlate with Ki67 276 in BC and healthy breast tissue? <sup>24</sup> Comparable questions arise regarding BC risk. Are there 277 biomarkers or even genes <sup>33</sup> which can recognize HT as cause of BCs? Can temporary growth 278 due to HT be recognized in the spatial spread of a BC? Today, molecular biological differences 279 in the BCs of HT users and non-users could improve our understanding of the effect. This may 280 also answer the question whether stopping HT can stop or even eradicate an autonomously 281 growing occult BC? <sup>2,34</sup> Comparisons with studies on estrogen treatment alone and the HT 282 different type and prescription and BC risk are obvious, especially as MWS and WHI are 283 contradictory in important aspects. <sup>5,7</sup> Hypothesis-based follow-up studies investigating BC risk 284 from the onset of HT could provide clarification. Particular attention should be paid to the first 285 286 months after screening-based recruitment and after the end of HT.

### 287 The view for patients

This reinterpretation of HT and BC risk may be relevant for patients. The decline in incidence 288 in 2002 shows that millions of women have stopped or not started HTs, predominantly from 289 fear of BCs. Women for whom HTs were indicated due to menopausal symptoms have 290 accepted a reduced quality of life <sup>3,35</sup>. The fear from BC needs to be put into perspective with 291 292 a modified understanding of the interrelation of its benefits and risks. Firstly, BCs which occur under HT are not caused by HT. At 5 years of HT, about 2 prevalent BCs are brought forward 293 for every 100 HT users. These BCs grow somewhat faster under HT. This may worsen the 294 295 prognosis. Therefore, annual screening for HT users would be beneficial. Secondly, there is also a BC risk due to HT. A RF of 2 would also lead to about 2 additional BCs per 100 HT 296 users, which, however, are not expected until 14 to 20 years later if short HTs are started at 297

the age of 50. Early detection and regular mammography screening can improve the prognosis
of these BCs. Risk reduction also includes the indication of endocrine prevention therapies, as
currently approved in postmenopausal women in the UK, in whom the number of prevalent
BCs can be almost halved, today perhaps with treatment of 2 years only (Fig.2A). <sup>12</sup>

#### 302 Limitations

As with all statistical modelling, the better the data, the more meaningful the results. This is related to the specification of the turning points at the end of the three Periods 1-3, which could not be derived from aggregating Forrest plots data, but from the time dependence of the cumulative incidence with a 30-year follow-up as shown in Fig. 2-3A. This would allow the growth duration of HR+ BCs and the range of HT-initiated BCs to be assigned more precisely.

The simulations show that the effects of HT can be modelled with the GAF and RF. A study "twin" with the same age distribution and the same long-term results can be generated for each of the non-consistent WHI cohorts. Incidence effects can also be explained with data on HT use in a population. Other modifying factors such as body mass index or a time dependency, e.g. on the gap between menopause and the start of HT, also require better data with correlating clinical findings.

#### 314 Conclusion

Modelling of correlations and hypotheses testing can be done by generating study twins using available data. This is demonstrated with a parameter constellation of the WHI-S. HTs promote and terminate the growth of prevalent BCs. Both, the renunciation of HT and its discontinuation caused the 10.3% decline in incidence in the USA in 2002. There is a BC risk, but it occurs with HT over a few years about 15 years after the onset of HT, probably with a factor of 2. The 1 million BCs attributed to HT are not newly caused, but prevalent BCs which have been shifted forward. The small additional time-delayed risk increases the benefit of short indicated HT. medRxiv preprint doi: https://doi.org/10.1101/2024.02.16.24302914; this version posted February 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

- Acknowledgment: We would like to thank all former MCR employees for their contributions to 322
- 323 the excellent data quality. We would like to thank Doris Mayr, Sylvia Heywang-Köbrunner,
- Christian Thaler and Michael Lauseker for their valuable scientific and technical advice. We 324
- thank the heads of the breast cancer project group of the Comprehensive Cancer Centre of 325
- the Ludwig-Maximilians-University and the Technical University of Munich for repeated 326
- 327 presentations and enriching discussions of results.
- 328
- 329 Funding: None
- 330
- 331 Conflict of Interest Disclosures: The authors declare no conflict of interest.
- 332
- Author Contributions: 333
- 334 Concept and design: Hölzel
- 335 Acquisition, analysis, interpretation of data: All authors
- 336 Drafting of the manuscript: All authors
- 337 Critical revision of the manuscript for intellectual content: Halfter, Schlesinger-Raab
- Statistical analysis: All authors 338
- 339 Administration, technical, material support: Halfter
- Supervision: Hölzel, Schlesinger-Raab 340
- 341

Figure 1: Tumor growth and growth acceleration by HT with GD 15 yrs, HTD 4 yrs and factor 2 for GAF 342 and RF. 343

344	A: HT begins at the age of 50 at time 0. The straight lines represent the number of cells with exponential
345	growth, the right axis shows the "age of development" of the prevalent BCs. If a BC is initiated 15 yrs
346	earlier, it is excluded due to positive mammography (red dot, a prevalent 1 mm BC which has grown
347	over 9.3 yrs from initiation and further 6 yrs until detection by mammography). BCs which start between -
348	15 and -11 yrs grow a maximum of 2 yrs faster under HT (orange trajectory) and are detected during HT.
349	BCs which are initiated before the start of HT (green) grow faster over 4 yrs at different tumor ages, their
350	growth slows again after the end of HT. Their detection is brought forward in time. The age-specific BCs
351	developing under HT (red trajectories) and additional BCs (blue) developing if there is a BC risk by HT
352	grow faster under HT. The first BCs initiated by HT would appear after about 13 yrs, the last after 19 yrs.
353	B: Transformation of the time of diagnosis of BC by HT. HT promotes tumor growth. Four periods can be
354	distinguished: P1 – Incidence increase with a RR of HTD/GAF. P2 – Same incidence until GD-
355	HTD*((GAF-1)/GAF) (2-13 years). P3a – Incidence decreases because diagnosis was brought forward
356	due to accelerated growth (green). P3b – HT induces new BCs (blue). P4 – End of HT effect. The
357	transformations and relative risks can be easily calculated if an annual incidence of e.g. 100 is assumed.







Figure 2: Simulation of incidence for 100,000 women aged 50 years with the model parameters GD 15 years, HTD 4 years, the factor 2 for GAF and RF and life expectancy. Overlapping lines were shifted manually.

362 A: Cumulative incidences generated according to the SEER data from 2000 (red) with 9,961 BCs or

11% over 30 years, with faster growth through 4 years of HT (green) with the same number and with an

additional BC risk (n=911) through HT (blue). With 2 years of endocrine prevention and 50% BC

- reduction, 2,731 or 27.4% of prevalent BCs could be avoided in 17 years (black). The 4 periods of Fig. 1
   are marked.
- **B:** The first 7 years of the cumulative incidences in Fig. 2A. Due to the inclusion criterion "negative
- 368 mammography", almost no BCs are diagnosed in the first six months without HT, but the first faster-

369 growing BCs are diagnosed after 3 months with HT.

370 **C:** Contours of the bar charts of the annual BCs: Without HT (red), with HT and GAF 2 (green), with HT,

GAF 2 and RF 2 (blue). The beginning and end of HT results in 4 periods: At the beginning by growth

acceleration of all prevalent BCs and with a time delay for the BCs occurring age-specifically under HT

and those initiated by HT, both of which are accelerated for 4 years and occur in P3 over 6 years. The

annual fluctuations are due to random generation (Poisson distributed: SD 19). The mammography

effect is evident in the first year. The absolute number of annual BCs decreases with age despite

increasing incidence because 27,612 women do not reach the age of 80 due to competing risk.

377 D: Time dependence of the relative risks with and without additional BC risk of HT and 95% CI. The

risks differ from the 13th year onwards. The inclusion criterion negative mammography and GAF 2 resultin the increased initial risk.



- Figure 3: Simulation of the randomized WHI study 382
- The model parameters are: 8,506 women (n=659/659/811/418 BCs in the four cohorts, see Fig.2), age 383
- distribution according to the WHI-S (MW: 63.6 yrs), GD 15 yrs (3.313 total yrs of tumor growth), HTD 5.6 384
- yrs (accelerated tumors n=379, total years of earlier detection =-682 yrs), negative mammogram, 385
- incidence according to SEER data from 2000, life expectancy considered as competing risk. They result 386
- in the estimates GAF 1.4 and RF 2.0 (+152 additional BCs). For a better overview overlapping lines 387
- were shifted manually. 388
- A: Cumulative incidences of the four groups. Control group of the WHI-S (red), and the HT groups 389
- without (green) and with BC risks (blue) show the combined effect for 30 years of follow-up. The turning 390
- points are at 4, 13.4 and 20.6 years. 391
- B: Cumulative incidences of the first 7 years. The effect of the negative mammogram is illustrated. 392
- 393 whereby no BCs occur in the control group in the first 6 months. In the control group 202 BCs were
- generated in 7 years, in the first year only 13 from day 186, in the HT group 249 and 13 appear before 394
- day 186 due to GAF 1.4. 395
- C: Contours of the bar charts of the annual BCs. Due to the higher age of 63.6 years, the number of 396 patients at risk and thus the annual BCs decrease significantly compared to Fig.2C. 397
- D: Time dependence of the relative risks with and without additional BC risk by HT and 95% CI (see 398 399 Fig.2)



medRxiv preprint doi: https://doi.org/10.1101/2024.02.16.24302914; this version posted February 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



All rights reserved. No reuse allowed without permission.

## 401 References

Lobo RA. Hormone-replacement therapy: current thinking. *Nature reviews Endocrinology* 2017; **13**(4): 220-31.
 Narod SA. Hormone replacement therapy and the risk of breast cancer. *Nature reviews Clinical oncology* 2011; **8**(11): 669-76.
 Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone
 therapy for perimenopausal and postmenopausal women. *The Cochrane database of*

408 *systematic reviews* 2017; **1**: Cd004143.

409 4. Writing Group for WHI Investigators. Risks and benefits of estrogen plus progestin in
410 healthy postmenopausal women: Principal results From the Women's Health Initiative
411 randomized controlled trial. *Jama* 2002; **288**(3): 321-33.

- 5. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal
  Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up
  of the Women's Health Initiative Randomized Clinical Trials. *Jama* 2020; **324**(4): 369-80.
- 6. Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause
  and breast-cancer risk by histological type: A cohort study and meta-analysis. *The Lancet*Oncology 2006; 7(11): 910-8.
- Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of
   menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of
   the worldwide epidemiological evidence. *Lancet* 2019; **394**: 1159-68.
- 421 8. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and 422 hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological
- studies of 52,705 women with breast cancer and 108,411 women without breast cancer.
  Collaborative Group on Hormonal Factors in Breast Cancer. *Lancet* 1997; **350**(9084): 104759.
- 426 9. Noone A, Howlader N, Krapcho M, Miller D, Brest Ae. SEER Cancer Statistics
   427 Review, 1975-2017 National Cancer Institute. Bethesda, MD,: http://seer.cancer.gov/
- 428 (accessed Feb. 5, 2024).

429 10. Munich Cancer Registry. http://www.tumorregister-

- 430 <u>muenchen.de/en/facts/specific\_analysis.php</u> (accessed Feb. 5, 2024).
- 431 11. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of
  432 developing breast cancer for white females who are being examined annually. *Journal of the*433 *National Cancer Institute* 1989; **81**(24): 1879-86.
- 434 12. Cuzick J, Sestak I, Forbes JF, et al. Use of anastrozole for breast cancer prevention 435 (IBIS-II): Long-term results of a randomised controlled trial. *Lancet* 2020; **395**: 117-22.
- 436 13. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast
  437 cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
  438 Journal of the National Cancer Institute 2005; 97(22): 1652-62.
- 439 14. Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S. Breast cancer tumor
  440 growth estimated through mammography screening data. *Breast cancer research : BCR*441 2008; **10**(3): R41.
- Ryu EB, Chang JM, Seo M, Kim SA, Lim JH, Moon WK. Tumour volume doubling
  time of molecular breast cancer subtypes assessed by serial breast ultrasound. *European radiology* 2014; **24**(9): 2227-35.
- 16. R Core Team. R: A language and environment for statistical computing. R:
- Foundation for Statistical Computing, Vienna, Austria. URL <u>http://www.R-project.org/</u>. 2015.
  17. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. *The New England journal of medicine* 2009; **360**(6): 573-87.
- 18. Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast
  cancer incidence and mortality in the Women's Health Initiative Observational Study. *Journal*of the National Cancer Institute 2013; **105**(8): 526-35.
- 453 19. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on
  454 breast cancer and mammography in healthy postmenopausal women: The Women's Health
  455 Initiative Randomized Trial. *Jama* 2003; **289**(24): 3243-53.

perpetuity. All rights reserved. No reuse allowed without permission.

20. Beral V. Breast cancer and hormone-replacement therapy in the Million Women 456

457 Study. Lancet 2003; 362(9382): 419-27.

Beral V, Peto R, Pirie K, Reeves G. Menopausal hormone therapy and 20-year breast 458 21. cancer mortality. Lancet 2019; 394(10204): 1139. 459

22. Engel J, Eckel R, Halfter K, Schubert-Fritschle G, Hölzel D. Breast cancer: emerging 460 461 principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data. 462 Journal of cancer research and clinical oncology 2022.

Wunderle M, Pretscher J, Brucker SY, et al. Association between breast cancer risk 463 23. factors and molecular type in postmenopausal patients with hormone receptor-positive early 464 465 breast cancer. Breast cancer research and treatment 2019; 174(2): 453-61.

Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone 466 24. replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is 467

associated with increased epithelial proliferation in the normal postmenopausal breast. The 468 Journal of clinical endocrinology and metabolism 1999; 84(12): 4559-65. 469

- 470 25. Engel J, Weichert W, Jung A, Emeny R, Hölzel D. Lymph node infiltration, parallel 471 metastasis and treatment success in breast cancer. Breast (Edinburgh, Scotland) 2019; 48: 472 1-6.
- 473 26. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast 474 cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
- 475 *Maturitas* 2006; **55**(2): 103-15.
- SEER NCI. Cancer Statistics Explorer Network. https://seer.cancer.gov/statistics-476 27. network/ (accessed Feb. 5, 2024. 477
- 478 28. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA: a cancer journal 479 for clinicians 2002; **52**(1): 23-47.
- 480 Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: a cancer journal for 29. 481 clinicians 2008; 58(2): 71-96.

Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 482 30. 483 2003 in the United States. The New England journal of medicine 2007; 356(16): 1670-4.

Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone 484 31.

- 485 therapy: annual trends and response to recent evidence. Jama 2004; 291(1): 47-53. 486 32. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for
- 487 secondary prevention of coronary heart disease in postmenopausal women. Heart and 488 Estrogen/progestin Replacement Study (HERS) Research Group. Jama 1998; 280(7): 605-489 13.
- 490 33. Narod SA. Which Genes for Hereditary Breast Cancer? The New England journal of 491 medicine 2021; 384(5): 471-3.
- 492 Shapiro S, Farmer RD, Seaman H, Stevenson JC, Mueck AO. Does hormone 34.
- 493 replacement therapy cause breast cancer? An application of causal principles to three 494 studies: Part 1. The Collaborative Reanalysis. The journal of family planning and
- reproductive health care 2011; 37(2): 103-9. 495

496 35. Pinkerton JV. Hormone Therapy for Postmenopausal Women. The New England 497 journal of medicine 2020; 382(5): 446-55.